Allergan Drug Buyers Take One Last Shot At Class Cert.
Purchasers of Allergan's ulcerative colitis drug lodged a last-ditch effort for class certification in their antitrust suit, asking a Massachusetts federal judge Monday to reconsider denying them a chance to rework...To view the full article, register now.
Already a subscriber? Click here to view full article